Immuno-oncology therapies: a looming mid-life crisis?

Hansoo Kim; Danny Liew; Stephen Goodall

Immuno-oncology therapies: a looming mid-life crisis?

Hansoo Kim
, Danny Liew
, Stephen Goodall

Research output: Contribution to journal › Comment/debate/opinion › Research › peer-review

1 Downloads (Pure)

Abstract

The introduction of immune-oncology therapies for the treatment of cancer marked a shift away from targeting cells to utilising the immune system to fight cancer. These therapies have become standard of care for many different tumour types [1] as they offer the possibility of long-term survival and improved toxicity profile for cancer patients when compared to chemotherapies.

Original language	English
Pages (from-to)	73-79
Number of pages	7
Journal	Immuno Oncology Insights
Volume	3
Issue number	2
Publication status	Published - 15 Mar 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

Immuno-oncology therapiesFinal published version, 467 KBLicence: CC BY-NC-ND

https://research-repository.griffith.edu.au/items/4089768e-6275-4e21-ac85-abb08d6aa77fLicence: Free to read

Cite this

@article{b2d00e1cd59e40d4ae7aa2cc2182d453,

title = "Immuno-oncology therapies: a looming mid-life crisis?",

abstract = "The introduction of immune-oncology therapies for the treatment of cancer marked a shift away from targeting cells to utilising the immune system to fight cancer. These therapies have become standard of care for many different tumour types [1] as they offer the possibility of long-term survival and improved toxicity profile for cancer patients when compared to chemotherapies.",

author = "Hansoo Kim and Danny Liew and Stephen Goodall",

year = "2022",

month = mar,

day = "15",

language = "English",

volume = "3",

pages = "73--79",

journal = "Immuno Oncology Insights",